Positive Development Raises $51.5M to Expand Autism Therapy Model

Wednesday, Aug 6, 2025 9:11 am ET1min read

Positive Development, a leading provider of developmental therapy for autistic children, has raised $51.5M in Series C funding. The company's model integrates speech, occupational, and mental health therapies with technology and real-time data to improve care quality and parent experience. The funding will be used to expand its DRBI-based care model, invest in new health plan and Medicaid partnerships, and advance its proprietary technology platform. Positive Development's model is 50% less expensive than traditional ABA interventions, addressing the crisis in the autism care market.

Positive Development, a leading provider of developmental therapy for autistic children, has raised $51.5M in Series C funding. The company's model integrates speech, occupational, and mental health therapies with technology and real-time data to improve care quality and parent experience. The funding will be used to expand its DRBI-based care model, invest in new health plan and Medicaid partnerships, and advance its proprietary technology platform.

Positive Development's model is 50% less expensive than traditional ABA interventions, addressing the crisis in the autism care market. The company's approach combines evidence-based therapies with real-time data collection to provide personalized care plans. This innovative model has shown promising results in improving outcomes for autistic children and reducing the financial burden on families.

The funding round was led by a prominent venture capital firm, with participation from several strategic investors. This infusion of capital will enable Positive Development to scale its operations, reach more families in need, and continue to innovate in the field of autism care.

Positive Development's success highlights the growing demand for affordable and effective autism care solutions. The company's ability to secure significant funding underscores investor confidence in its unique approach and potential for market disruption.

References:
[1] https://nevadaautism.com/autism-a-closer-look-at-four-subtypes/
[2] https://www.stocktitan.net/news/IMMP/immutep-receives-positive-feedback-from-fda-on-late-stage-clinical-qk17pahwvxqx.html

Comments



Add a public comment...
No comments

No comments yet